CN101415426A - c-Src抑制剂与嘧啶基氨基苯甲酰胺类化合物的组合治疗白血病的用途 - Google Patents

c-Src抑制剂与嘧啶基氨基苯甲酰胺类化合物的组合治疗白血病的用途 Download PDF

Info

Publication number
CN101415426A
CN101415426A CNA2007800120868A CN200780012086A CN101415426A CN 101415426 A CN101415426 A CN 101415426A CN A2007800120868 A CNA2007800120868 A CN A2007800120868A CN 200780012086 A CN200780012086 A CN 200780012086A CN 101415426 A CN101415426 A CN 101415426A
Authority
CN
China
Prior art keywords
compound
leukemia
src
formula
activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2007800120868A
Other languages
English (en)
Chinese (zh)
Inventor
P·W·曼雷
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN101415426A publication Critical patent/CN101415426A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CNA2007800120868A 2006-04-07 2007-04-05 c-Src抑制剂与嘧啶基氨基苯甲酰胺类化合物的组合治疗白血病的用途 Pending CN101415426A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79043706P 2006-04-07 2006-04-07
US60/790,437 2006-04-07

Publications (1)

Publication Number Publication Date
CN101415426A true CN101415426A (zh) 2009-04-22

Family

ID=38512209

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2007800120868A Pending CN101415426A (zh) 2006-04-07 2007-04-05 c-Src抑制剂与嘧啶基氨基苯甲酰胺类化合物的组合治疗白血病的用途

Country Status (11)

Country Link
US (2) US20100152198A1 (enExample)
EP (1) EP2010182A2 (enExample)
JP (2) JP2009532438A (enExample)
KR (2) KR20090031855A (enExample)
CN (1) CN101415426A (enExample)
AU (1) AU2007235976A1 (enExample)
BR (1) BRPI0710675A2 (enExample)
CA (1) CA2644841C (enExample)
MX (1) MX2008012903A (enExample)
RU (2) RU2008143703A (enExample)
WO (1) WO2007116025A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116178358A (zh) * 2022-11-04 2023-05-30 济南大学 一种靶向c-Src激酶SH3结构域的化合物及其应用

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1848414T3 (da) 2005-02-03 2011-07-25 Gen Hospital Corp Fremgangsmåde til behandling af gefitinib-resistent cancer
AU2006311877A1 (en) 2005-11-04 2007-05-18 Wyeth Llc Antineoplastic combinations with mTOR inhibitor, herceptin, and/orHKI-272
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
SI2310011T1 (sl) 2008-06-17 2013-10-30 Wyeth Llc Antineoplastične kombinacije, ki vsebujejo HKI-272 in vinorelbin
BRPI0916694B1 (pt) * 2008-08-04 2021-06-08 Wyeth Llc uso de neratinibe em combinação com capecitabina para tratar câncer de mama metastático de erbb-2 positivo, kit e produto compreendendo os mesmos
EA201890869A3 (ru) 2010-06-03 2019-03-29 Фармасайкликс, Инк. Применение ингибиторов тирозинкиназы брутона (btk)
WO2014018567A1 (en) 2012-07-24 2014-01-30 Pharmacyclics, Inc. Mutations associated with resistance to inhibitors of bruton's tyrosine kinase (btk)
CN103113355B (zh) * 2013-02-27 2014-08-13 无锡爱内特生物科技有限公司 一种Bcr/Abl酪氨酸激酶抑制剂及其制备方法和在治疗慢性粒细胞白血病中的应用
US20170114323A1 (en) 2014-06-19 2017-04-27 Whitehead Institute For Biomedical Research Uses of kinase inhibitors for inducing and maintaining pluripotency
US12371667B2 (en) 2021-05-13 2025-07-29 Washington University Enhanced methods for inducing and maintaining naive human pluripotent stem cells

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH690773A5 (de) * 1996-02-01 2001-01-15 Novartis Ag Pyrrolo(2,3-d)pyrimide und ihre Verwendung.
WO2002000024A1 (en) * 2000-06-30 2002-01-03 The Regents Of The University Of California New strategy for leukemia therapy
WO2002062334A2 (en) * 2001-02-05 2002-08-15 Pezzuto John M Cancer chemopreventative compounds and compositions and methods of treating cancers
AU2002345670A1 (en) * 2001-06-14 2003-01-02 The Regents Of The University Of California Mutations in the bcr-abl tyrosine kinase associated with resistance to sti-571
EP1418917A1 (en) * 2001-08-10 2004-05-19 Novartis AG Use of c-src inhibitors alone or in combination with sti571 for the treatment of leukaemia
EP1473043A1 (en) * 2003-04-29 2004-11-03 Boehringer Ingelheim Pharma GmbH & Co.KG Pharmaceutical combination for the treatment of diseases involving cell proliferation, migration or apotosis of myeloma cells, or angiogenesis
AU2003291245A1 (en) * 2003-11-06 2004-06-06 Wyeth 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (cml)
US20060069101A1 (en) * 2004-09-27 2006-03-30 Kim Kyoung S Prodrugs of protein tyrosine kinase inhibitors
US20060235006A1 (en) * 2005-04-13 2006-10-19 Lee Francis Y Combinations, methods and compositions for treating cancer
GT200600315A (es) * 2005-07-20 2007-03-19 Formas cristalinas de 4-metilo-n-[3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo]-3-(4-pyridina-3-ilo-pirimidina-2-iloamino)-benzamida
GT200600316A (es) * 2005-07-20 2007-04-02 Sales de 4-metilo-n-(3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo)-3-(4-piridina-3-ilo-pirimidina-2-iloamino)- benzamida.

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116178358A (zh) * 2022-11-04 2023-05-30 济南大学 一种靶向c-Src激酶SH3结构域的化合物及其应用
CN116178358B (zh) * 2022-11-04 2024-04-19 济南大学 一种靶向c-Src激酶SH3结构域的化合物及其应用

Also Published As

Publication number Publication date
BRPI0710675A2 (pt) 2011-08-23
KR20110097966A (ko) 2011-08-31
CA2644841A1 (en) 2007-10-18
MX2008012903A (es) 2008-10-13
KR20090031855A (ko) 2009-03-30
KR101292508B1 (ko) 2013-08-01
RU2008143703A (ru) 2010-05-20
RU2012147511A (ru) 2014-05-20
WO2007116025A3 (en) 2007-12-13
WO2007116025A2 (en) 2007-10-18
AU2007235976A1 (en) 2007-10-18
US20100152198A1 (en) 2010-06-17
US20130040972A1 (en) 2013-02-14
JP2009532438A (ja) 2009-09-10
JP2013136596A (ja) 2013-07-11
EP2010182A2 (en) 2009-01-07
CA2644841C (en) 2013-07-16

Similar Documents

Publication Publication Date Title
KR101292508B1 (ko) 백혈병의 치료를 위한, 피리미딜아미노벤즈아미드 화합물과 조합된 ｃ-ｓｒｃ 억제제의 용도
CA2450777C (en) Use of c-src inhibitors alone or in combination with sti571 for the treatment of leukaemia
JP2013127001A (ja) ピリミジルアミノベンズアミド化合物であるタンパク質キナーゼ阻害剤および１７−ａａｇのようなｈｓｐ９０阻害剤を含む組合せ剤
EP2007391B1 (en) Combination comprising a) a pyrimidylaminobenzamide compound, and b) a thr315lle kinase inhibitor
US20080255171A1 (en) Combination of Nilotinib with Farnesyl Transferase Inhibitors
NZ563446A (en) Combination of pyrimidylaminobenzamide compounds and imatinib for treating or preventing proliferative diseases
AU2011202950B2 (en) Use of c-Src inhibitors in combination with a pyrimidylaminobenzamide compound for the treatment of leukemia
WO2007051862A1 (en) Combination of organic compounds
AU2013201915A1 (en) Use of c-Src inhibitors in combination with a pyrimidylaminobenzamide compound for the treatment of leukemia
AU2006271651A1 (en) Combination comprising a pyrimidylaminobenzamides and a Flt-3 inhibitor for treating proliferative diseases
CN101222925A (zh) 嘧啶基氨基苯甲酰胺和mTOR激酶抑制剂的组合产品
EP1863491A1 (en) Pharmaceutical combination of bcr-abl and raf inhibitors
CN101484172A (zh) 包含a)嘧啶基氨基苯甲酰胺化合物和b)thr315lle激酶抑制剂的组合
HK1146804A (en) Use of c-src inhibitors alone or in combination with sti571 for the treatment of leukaemia

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20090422